Immatics N.V. (IMTX)

NASDAQ: IMTX · IEX Real-Time Price · USD
7.13
0.18 (2.59%)
May 25, 2022 4:30 PM EDT - Market closed
Market Cap448.67M
Revenue (ttm)34.76M
Net Income (ttm)-93.34M
Shares Out62.93M
EPS (ttm)-1.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume87,366
Open7.03
Previous Close6.95
Day's Range6.90 - 7.72
52-Week Range5.75 - 16.30
Beta0.42
AnalystsBuy
Price Target24.14 (+238.6%)
Earnings DateMay 31, 2022

About IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients wi...

IndustryBiotechnology
Employees188
Stock ExchangeNASDAQ
Ticker SymbolIMTX
Full Company Profile

Financial Performance

In 2021, Immatics's revenue was $34.76 million, an increase of 11.23% compared to the previous year's $31.25 million. Losses were -$93.34 million, -55.82% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for IMTX stock is "Buy." The 12-month stock price forecast is 24.14, which is an increase of 238.57% from the latest price.

Price Target
$24.14
(238.57% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo...

H ouston, Texas and Tuebingen , Germany , May XX , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

1 week ago - GlobeNewsWire

Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 week ago - Zacks Investment Research

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Tuebingen , Germany and Houston, Texas , May 10 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirectin...

2 weeks ago - GlobeNewsWire

Wall Street Analysts See a 178% Upside in Immatics (IMTX): Can the Stock Really Move This High?

The consensus price target hints at a 178.1% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

1 month ago - Zacks Investment Research

Immatics Announces Full Year 2021 Financial Results and Corporate Update

Tuebingen , Germany and Houston, TX , March 2 3 , 20 2 2 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirect...

2 months ago - GlobeNewsWire

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

Tuebingen , Germany and Houston, TX , November 16 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redire...

6 months ago - GlobeNewsWire

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Tar...

Company to host conference call on Tuesday, November 9 at 8:30 am EST

6 months ago - GlobeNewsWire

Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Canc...

Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...

6 months ago - GlobeNewsWire

Immatics (IMTX) Stock Jumps 5.8%: Will It Continue to Soar?

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

6 months ago - Zacks Investment Research

Immatics: Q2 Earnings Insights

Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 21.62% year over year to ($0.45), which missed the estimate of ($0.40).

9 months ago - Benzinga

Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

Tuebingen, Germany and Houston, TX, August 10, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting c...

9 months ago - GlobeNewsWire

BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions

Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs).

10 months ago - Benzinga

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

BASEL, Switzerland and TÜBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell recept...

10 months ago - PRNewsWire

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispeci...

GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences companies, announced today that they have signed service agreements with Immatics N.V. (NASDAQ: IMTX; “...

10 months ago - Business Wire

Immatics Announces Changes to its Board of Directors

Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirectin...

11 months ago - GlobeNewsWire

Immatics Announces First Quarter 2021 Financial Results and Business Update

Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting...

1 year ago - GlobeNewsWire

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Immatics' second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor model

1 year ago - GlobeNewsWire

Immatics Announces Full Year 2020 Financial Results and Corporate Update

Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting ca...

1 year ago - GlobeNewsWire

Why Immatics Stock Is Soaring Today

Investors liked the company's latest clinical update.

1 year ago - The Motley Fool

IMTX Stock: Why Immatics Shares Are Rocketing Higher Today

A press release from the company is showing promise in shrinking cancerous tumors. The discoveries are leading to a rise in IMTX stock.

1 year ago - InvestorPlace

Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients

Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203. Data...

1 year ago - Benzinga

Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday

bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.

Other symbols:BLUEHUGEONTX
1 year ago - Benzinga

3 Biotech Stocks That Could Double In 12 Months

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...

Other symbols:FGENREPL
1 year ago - Benzinga